Innate Pharma

Innate Pharma announces its financial calendar for 2017

January 4, 2017

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH) today announces its financial calendar for 2017, which is set as follows: March 7, 2017 : Publication of 2016 financial statements...

Innate Pharma announces conference call and webcast

August 14, 2026

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), today announces that the Company will hold a conference call on Friday, August 14, 2026 at 2:00 p.m. CEST / 8:00 a...

Innate Pharma Announces Pricing of €30 million Offering of Ordinary Shares

August 14, 2026

Addendum NOT FOR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (" Innate " or the " Company "), today announced the...

Innate Pharma Announces Proposed Offering of Ordinary Shares

August 13, 2026

NOT FOR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA, SOUTH AFRICA OR JAPAN Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (" Innate " or the " Company "), today announced the launch of...

Innate Pharma to advance Lacutamab towards phase 3 following partnership with Sobi and appoints new chief medical officer

August 10, 2026

Innate to advance lacutamab towards TELLOMAK-3 Phase 3 following the partnership with Sobi, a key step toward the filing for accelerated approval in Sézary syndrome Markus Jensen appointed Chief...

Innate Pharma enters strategic partnership with Sobi to license lacutamab in T-cell lymphoma

August 10, 2026

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") and Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced that they have entered a strategic partnership to enable...

Innate Pharma to participate in a bladder cancer panel at the BTIG Virtual Biotechnology Conference

July 23, 2026

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that Sonia...

Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)

July 21, 2026

Enrollment completed in the dose escalation of IPH4502-101 study, with preliminary data readout from 76 patients expected by year-end Favorable safety profile observed to date, with limited...

Outcome of Innate Pharma’s 2026 Annual General Meeting

May 22, 2026

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 21...

Innate Pharma to participate in the Jefferies Global Healthcare Conference

May 19, 2026